THOMAS E WITZIG, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 27220
Category
Osteopathic Medicine
Type
Hematology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about THOMAS E WITZIG at bizstanding.comMayo Clinic - Thomas E Witzig MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 284-2017 (Phone)
Professional information
Dr. Thomas E Witzig, Rochester MN - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Hematology, 1984, Internal Medicine, 1982, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Illinois College Of Medicine Chicago
Graduated: 1979
University Ia Hospital
Graduated: 1980
Graduated: 1982
Mayo Clinic Rochester
Graduated: 1986
University Of Illinois College Of Medicine Chicago
Graduated: 1979
University Ia Hospital
Graduated: 1980
Graduated: 1982
Mayo Clinic Rochester
Graduated: 1986
Thomas E Witzig, Rochester MN
Specialties:
Internal Medicine, Hematology, Medical Oncology, Pathology, Public Health & General Preventive Medicine
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
University of Illinois at Chicago (1979)
Probiotic Mixture Intended For Monogastric Animals To Control Intestinal Flora Populations
US Patent:
6524574, Feb 25, 2003
Filed:
May 29, 1998
Appl. No.:
09/087792
Inventors:
David A. Spangler - Fulton IL
Patrick K. Brown - Fulton IL
Thomas E. Witzig - Rochester MN
Patrick K. Brown - Fulton IL
Thomas E. Witzig - Rochester MN
Assignee:
Agri-King, Inc. - Fulton IL
Mayo Foundation for Medical Education and Research - Rochester MN
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A01N 6300
US Classification:
424 933, 424 9345, 424 9351, 424 9348
Abstract:
A mixture of probiotics effective to reduce the contamination of enteric bacteria in humans and other monogastric animals. The mixture of probiotics includes a lactic acid-producing bacteria and a yeast, and may advantageously be supplemented with a source of nutrients, such as lactose, in certain applications. In a preferred embodiment, the bacterial component is at least one strain of Enterococci, the yeast is at least one strain of Saccharomyces, and a high lactose whey.
Depleting Immunosuppressive Monocytes Within A Mammal
US Patent:
2012017, Jul 5, 2012
Filed:
Sep 7, 2010
Appl. No.:
13/394787
Inventors:
Ryan A. Wilcox - Rochester MN, US
Thomas E. Witzig - Rochester MN, US
Thomas E. Witzig - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 39/395, A61P 35/00, A61P 29/00, A61P 37/04
US Classification:
4241341
Abstract:
This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD14/DR or CD14/DRmonocytes) within a mammal. For example, methods and materials involved in using a CD2 binding molecule (e.g., alefacept) to deplete immunosuppressive monocytes within a mammal (e.g., a human) are provided.
Probiotic Mixture Intended For Monogastric Animals To Control Intestinal Flora Populations
US Patent:
6841149, Jan 11, 2005
Filed:
Jul 24, 2002
Appl. No.:
10/202159
Inventors:
David A. Spangler - Sterling IL, US
Patrick K. Brown - Camanche IA, US
Thomas E. Witzig - Rochester MN, US
Patrick K. Brown - Camanche IA, US
Thomas E. Witzig - Rochester MN, US
Assignee:
Agri-King, Inc. - Fulton IL
Mayo Foundation for Medical Education and Research - Rochester MN
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A01N 6300
US Classification:
424 933, 424 9345, 424 9351, 424 9348, 4352524
Abstract:
A mixture of probiotics effective to reduce the contamination of enteric bacteria in humans and other monogastric animals. The mixture of probiotics includes one or more acid-producing bacteria strains and one or more yeast strains, and may advantageously be supplemented with a source of nutrients, such as prebiotics including fructo-oligosaccharides. In a preferred embodiment, said one or more bacteria strains contain strain NCIMB #10415, and said one or more yeast strains contain NCYC #47 and CNCM I-1079.
Method Of Treating Mantle Cell Lymphoma
US Patent:
8507518, Aug 13, 2013
Filed:
Apr 1, 2011
Appl. No.:
13/078272
Inventors:
Thomas E. Witzig - Rochester MN, US
Scott H. Kaufmann - Rochester MN, US
Scott H. Kaufmann - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 31/44
US Classification:
514291
Abstract:
This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.
Method Of Treating Mantle Cell Lymphoma
US Patent:
2005011, May 26, 2005
Filed:
Nov 2, 2004
Appl. No.:
10/979284
Inventors:
Thomas Witzig - Rochester MN, US
Scott Kaufmann - Rochester MN, US
Scott Kaufmann - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K031/4745
US Classification:
514291000
Abstract:
This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.